Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 7.441
Filtrer
1.
Viruses ; 16(6)2024 Jun 11.
Article de Anglais | MEDLINE | ID: mdl-38932232

RÉSUMÉ

Background: The effects of antihistamines on cancer risk and prognosis have been inconsistent across cancers. The aim of this multi-center cohort study was to investigate the association between antihistamine use and the risk of liver cancer in individuals with viral hepatitis. Methods: This multi-center cohort study included individuals diagnosed with hepatitis B or hepatitis C between January 2008 and March 2022. For antihistamine-treated patients, the index date was the date of antihistamine prescription, and for non-users, it was the date of hepatitis diagnosis. Participants were followed for five years, with the primary outcome of interest being new-onset liver cancer. The incidence rate and the adjusted hazard ratio (aHR) along with its 95% confidence interval (CI) of the outcome were calculated. Subgroup analyses were conducted, stratified by types of viral hepatitis including hepatitis C and hepatitis B. An additional validation study was performed. Results: The study included a total of 7748 patients with viral hepatitis. The incidence rate was 12.58 per 1000 person-years in patients with viral hepatitis on antihistamines, compared to 3.88 per 1000 person-years in those without antihistamine use. After adjusting for factors including age, sex, body mass index (BMI), comorbidities, laboratory data of liver function tests, comedications, and the use of antiviral therapies, the risk of new-onset liver cancer was significantly higher in patients on antihistamines (aHR = 1.83, 95% CI, 1.28-2.60). In patients with hepatitis C, the incidence rate in the antihistamine group was 15.73 per 1000 person-years, while non-users had a rate of 4.79 per 1000 person-years. Patients with hepatitis C on antihistamines had a significantly higher risk of developing liver cancer (aHR = 3.24, 95% CI, 2.16-4.86). Conclusions: This multi-center cohort study reported an increased risk of liver cancer in patients with hepatitis B or hepatitis C treated with antihistamines. Long-term follow-up studies are warranted to validate the findings.


Sujet(s)
Antihistaminiques , Tumeurs du foie , Humains , Femelle , Mâle , Antihistaminiques/usage thérapeutique , Antihistaminiques/effets indésirables , Tumeurs du foie/épidémiologie , Tumeurs du foie/étiologie , Adulte d'âge moyen , Incidence , Études de cohortes , Facteurs de risque , Adulte , Hépatite C/complications , Hépatite C/traitement médicamenteux , Hépatite B/complications , Hépatite B/épidémiologie , Sujet âgé
2.
J Natl Compr Canc Netw ; 22(2D)2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38862004

RÉSUMÉ

BACKGROUND: Type 2 diabetes mellitus (T2DM) may be a risk factor for development of hepatocellular carcinoma (HCC). The association between risk of developing HCC and treatment with sodium-glucose cotransporter-2 inhibitors (SGLT2i) versus dipeptidyl peptidase-4 inhibitors (DPP4i) is currently unknown. This study aimed to compare the risk of new-onset HCC in patients treated with SGLT2i versus DPP4i. METHODS: This was a retrospective cohort study of patients with T2DM in Hong Kong receiving either SGLT2i or DPP4i between January 1, 2015, and December 31, 2020. Patients with concurrent DPP4i and SGLT2i use were excluded. Propensity score matching (1:1 ratio) was performed by using the nearest neighbor search. Multivariable Cox regression was applied to identify significant predictors. RESULTS: A total of 62,699 patients were included (SGLT2i, n=22,154; DPP4i, n=40,545). After matching (n=44,308), 166 patients (0.37%) developed HCC: 36 in the SGLT2i group and 130 in the DPP4i group over 240,269 person-years. Overall, SGLT2i use was associated with lower risks of HCC (hazard ratio [HR], 0.42; 95% CI, 0.28-0.79) compared with DPP4i after adjustments. The association between SGLT2i and HCC development remained significant in patients with cirrhosis or advanced fibrosis (HR, 0.12; 95% CI, 0.04-0.41), hepatitis B virus (HBV) infection (HR, 0.32; 95% CI, 0.17-0.59), or hepatitis C virus (HCV) infection (HR, 0.41; 95% CI, 0.22-0.80). The results were consistent in different risk models, propensity score approaches, and sensitivity analyses. CONCLUSIONS: SGLT2i use was associated with a lower risk of HCC compared with DPP4i use after adjustments, and in the context of cirrhosis, advanced fibrosis, HBV infection, and HCV infection.


Sujet(s)
Carcinome hépatocellulaire , Diabète de type 2 , Inhibiteurs de la dipeptidyl-peptidase IV , Tumeurs du foie , Inhibiteurs du cotransporteur sodium-glucose de type 2 , Humains , Carcinome hépatocellulaire/épidémiologie , Carcinome hépatocellulaire/étiologie , Carcinome hépatocellulaire/virologie , Inhibiteurs du cotransporteur sodium-glucose de type 2/usage thérapeutique , Inhibiteurs du cotransporteur sodium-glucose de type 2/effets indésirables , Tumeurs du foie/épidémiologie , Tumeurs du foie/étiologie , Diabète de type 2/traitement médicamenteux , Diabète de type 2/complications , Mâle , Femelle , Inhibiteurs de la dipeptidyl-peptidase IV/usage thérapeutique , Inhibiteurs de la dipeptidyl-peptidase IV/effets indésirables , Études rétrospectives , Adulte d'âge moyen , Sujet âgé , Facteurs de risque
3.
BMC Med ; 22(1): 261, 2024 Jun 24.
Article de Anglais | MEDLINE | ID: mdl-38915009

RÉSUMÉ

BACKGROUND: To assess the largely undetermined separate and joint effects of sleep and liver function biomarkers on liver cancer. METHODS: Data of 356,894 participants without cancer at baseline in the UK Biobank were analyzed. Sleep score was evaluated using five sleep traits (sleep duration, chronotype, insomnia, snoring, and excessive daytime sleepiness) and dichotomized into healthy or unhealthy sleep. Circulating liver function biomarkers were measured. Cox proportional hazard model was performed to investigate the independent and joint associations of sleep and liver function biomarkers with liver cancer incidence. RESULTS: After a median follow-up time of 13.1 years, 394 cases of incident liver cancer were documented. The multivariable-adjusted hazard ratio (HR) for liver cancer was 1.46 (95% confidence interval: 1.15-1.85) associated with unhealthy sleep (vs. healthy sleep), and was 1.17 (1.15-1.20), 1.20 (1.18-1.22), 1.69 (1.47-1.93), 1.06 (1.06-1.07), 1.08 (1.07-1.09), 1.81 (1.37-2.39), or 0.29 (0.18-0.46) associated with each 10-unit increase in alanine transaminase (ALT), aspartate transaminase (AST), total bilirubin (TBIL), gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP), total protein (TP), or albumin (ALB), respectively. Individuals with unhealthy sleep and high (≥ median) ALT, AST, TBIL, GGT, ALP, or TP or low (< median) ALB level had the highest HR of 3.65 (2.43-5.48), 4.03 (2.69-6.03), 1.97 (1.40-2.77), 4.69 (2.98-7.37), 2.51 (1.75-3.59), 2.09 (1.51-2.89), or 2.22 (1.55-3.17) for liver cancer, respectively. Significant additive interaction of unhealthy sleep with high TP level on liver cancer was observed with relative excess risk due to an interaction of 0.80 (0.19-1.41). CONCLUSIONS: Unhealthy sleep was associated with an increased risk of liver cancer, especially in participants with lower ALB levels or higher levels of ALT, AST, TBIL, GGT, ALP, or particularly TP.


Sujet(s)
Marqueurs biologiques , Tumeurs du foie , Sommeil , Humains , Mâle , Femelle , Adulte d'âge moyen , Tumeurs du foie/épidémiologie , Tumeurs du foie/sang , Études prospectives , Sommeil/physiologie , Marqueurs biologiques/sang , Sujet âgé , Royaume-Uni/épidémiologie , Adulte , Incidence , Tests de la fonction hépatique , Facteurs de risque , Foie
4.
Eur J Med Res ; 29(1): 343, 2024 Jun 21.
Article de Anglais | MEDLINE | ID: mdl-38902822

RÉSUMÉ

As a hepatotropic virus, hepatitis B virus (HBV) can establish a persistent chronic infection in the liver, termed, chronic hepatitis B (CHB), which causes a series of liver-related complications, including fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). HCC with HBV infection has a significantly increased morbidity and mortality, whereas it could be preventable. The current goal of antiviral therapy for HBV infection is to decrease CHB-related morbidity and mortality, and achieve sustained suppression of virus replication, which is known as a functional or immunological cure. The natural history of chronic HBV infection includes four immune phases: the immune-tolerant phase, immune-active phase, inactive phase, and reactivation phase. However, many CHB patients do not fit into any of these defined phases and are regarded as indeterminate. A large proportion of indeterminate patients are only treated with dynamic monitoring rather than recommended antiviral therapy, mainly due to the lack of definite guidelines. However, many of these patients may gradually have significant liver histopathological changes during disease progression. Recent studies have focused on the prevalence, progression, and carcinogenicity of indeterminate CHB, and more attention has been given to the prevention, detection, and treatment for these patients. Herein, we discuss the latest understanding of the epidemiology, clinical characteristics, and therapeutic strategies of indeterminate CHB, to provide avenues for the management of these patients.


Sujet(s)
Antiviraux , Virus de l'hépatite B , Hépatite B chronique , Humains , Hépatite B chronique/épidémiologie , Hépatite B chronique/traitement médicamenteux , Hépatite B chronique/complications , Antiviraux/usage thérapeutique , Virus de l'hépatite B/pathogénicité , Virus de l'hépatite B/physiologie , Tumeurs du foie/épidémiologie , Tumeurs du foie/thérapie , Tumeurs du foie/virologie , Tumeurs du foie/étiologie , Carcinome hépatocellulaire/épidémiologie , Carcinome hépatocellulaire/thérapie , Carcinome hépatocellulaire/étiologie , Carcinome hépatocellulaire/virologie , Cirrhose du foie/épidémiologie , Cirrhose du foie/virologie , Évolution de la maladie
5.
BMC Cancer ; 24(1): 694, 2024 Jun 06.
Article de Anglais | MEDLINE | ID: mdl-38844890

RÉSUMÉ

BACKGROUND: Hepatocellular Carcinoma (HCC) can be classified as one of the most common malignancies worldwide. There is scarcity of the published data on the risk factors for HCC in the Gulf Cooperation Council countries specifically Kuwait. Therefore, this case-control study sought to examine the risk factors associated with HCC in Kuwait. METHODS: Fifty-three histopathologically confirmed HCC cases were recruited from the Kuwait Cancer Control Center Registry. One hundred ninety-six controls (1:4 ratio) were selected from medical and/ or surgical outpatient's clinics at all six public hospitals of Kuwait. A structured questionnaire was used to collect the data both from cases and controls through face-to-face interviews. A multivariable logistic regression model was fitted to the case-control data. Adjusted odds ratios (ORadj) and their 95% confidence intervals (CI) were computed using the parameters' estimates of the final model and used for interpretation of the model. RESULTS: The HCC cases compared with the controls were 41.6 times more likely to have had the history of non-alcoholic fatty liver disease (NAFLD) (ORadj = 41.6; 95% CI: 8.9-193.5; p < 0.001). The cases compared with the controls were more likely to have reported the history of heavy alcohol drinking (ORadj = 14.2; 95% CI: 1.2-173.4; p = 0.038). Furthermore, compared with the controls, the HCC cases tended to frequently consume milk and/or milk substitutes (≥ 3 glass/ week) (ORadj = 7.2; 95% CI: 1.2-43.4). Conversely however, there was a significant protective effect if the participants reportedly have had regularly used olive oil in their routine diet as a source of fat (ORadj = 0.17; 95% CI: 0.04-0.80) or regularly used non-steroid anti-inflammatory drugs (NSAIDs) (ORadj = 0.20; 95% CI: 0.05-0.71). CONCLUSIONS: This study showed that heavy alcohol consumption, NAFLD history, and excessive consumption of milk/ milk substitutes were associated with a significantly increased HCC risk. Conversely however, regular use of olive oil in the diet as a source of fat or regular use of NSAIDs had a significantly protective effect against HCC risk. Adapting healthy dietary habits and preventing/ treating NAFLD may minimize the HCC risk. Future research with a larger sample size may contemplate validating the results of this study and unraveling additional risk factors contributing to HCC risk. The resultant data may help design and implement evidence-based educational programs for the prevention of HCC in this and other similar settings.


Sujet(s)
Carcinome hépatocellulaire , Régime alimentaire , Mode de vie , Tumeurs du foie , Humains , Carcinome hépatocellulaire/épidémiologie , Carcinome hépatocellulaire/étiologie , Tumeurs du foie/épidémiologie , Femelle , Mâle , Études cas-témoins , Adulte d'âge moyen , Facteurs de risque , Koweït/épidémiologie , Sujet âgé , Comorbidité , Adulte , Consommation d'alcool/effets indésirables , Consommation d'alcool/épidémiologie , Stéatose hépatique non alcoolique/épidémiologie
6.
Front Endocrinol (Lausanne) ; 15: 1411706, 2024.
Article de Anglais | MEDLINE | ID: mdl-38846491

RÉSUMÉ

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) constitutes the commonest cause of chronic liver disorder worldwide, whereby affecting around one third of the global population. This clinical condition may evolve into Metabolic Dysfunction-Associated Steatohepatitis (MASH), fibrosis, cirrhosis and hepatocellular carcinoma (HCC), in a predisposed subgroup of patients. The complex pathogenesis of MASLD is severely entangled with obesity, dyslipidemia and type 2 diabetes (T2D), so far so nutritional and lifestyle recommendations may be crucial in influencing the risk of HCC and modifying its prognosis. However, the causative association between HCC onset and the presence of metabolic comorbidities is not completely clarified. Therefore, the present review aimed to summarize the main literature findings that correlate the presence of inherited or acquired hyperlipidemia and metabolic risk factors with the increased predisposition towards liver cancer in MASLD patients. Here, we gathered the evidence underlining the relationship between circulating/hepatic lipids, cardiovascular events, metabolic comorbidities and hepatocarcinogenesis. In addition, we reported previous studies supporting the impact of triglyceride and/or cholesterol accumulation in generating aberrancies in the intracellular membranes of organelles, oxidative stress, ATP depletion and hepatocyte degeneration, influencing the risk of HCC and its response to therapeutic approaches. Finally, our pursuit was to emphasize the link between HCC and the presence of cardiometabolic abnormalities in our large cohort of histologically-characterized patients affected by MASLD (n=1538), of whom 86 had MASLD-HCC by including unpublished data.


Sujet(s)
Carcinome hépatocellulaire , Facteurs de risque cardiométabolique , Tumeurs du foie , Humains , Carcinome hépatocellulaire/métabolisme , Carcinome hépatocellulaire/épidémiologie , Carcinome hépatocellulaire/étiologie , Carcinome hépatocellulaire/anatomopathologie , Tumeurs du foie/métabolisme , Tumeurs du foie/épidémiologie , Tumeurs du foie/étiologie , Stéatose hépatique/complications , Stéatose hépatique/métabolisme , Stéatose hépatique/anatomopathologie , Stéatose hépatique/épidémiologie , Diabète de type 2/complications , Diabète de type 2/métabolisme , Facteurs de risque
7.
J Manag Care Spec Pharm ; 30(6): 572-580, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38824631

RÉSUMÉ

BACKGROUND: New cancer diagnoses are associated with employment decrease, workplace absenteeism, and attributable costs to employers. OBJECTIVE: To estimate the workplace productivity loss in the year following a new diagnosis of early-, intermediate-, or advanced-stage hepatocellular carcinoma (HCC) in commercially insured US adults. METHODS: We conducted a retrospective cohort study using Merative MarketScan commercial claims to identify incident HCC diagnoses from 2010 to 2020. Patients were stratified into early-, intermediate-, or advanced-stage cohorts based on presence of secondary malignancy codes or first treatment received. Mean workdays lost and attributable cost in the year following a new diagnosis were calculated using the Kaplan-Meier sample averages to account for censoring. An exploratory analysis was conducted on subgroups in the early and advanced cohorts to assess productivity loss in patients with and without treatment. RESULTS: Mean workdays lost in the year following a new HCC diagnosis among the early, intermediate, and advanced cohorts was 22.6 days (95% CI = 16.0-29.8), 17.4 days (95% CI = 11.9-23.2), and 19.5 days (95% CI = 15.6-23.6), respectively. Corresponding indirect costs were $6,031(95% CI = $4,270-$7,953), $4,644 (95% CI = $3,176-$6,192), and $5,204 (95% CI = $4,163-$6,298). Early-stage patients without a liver transplant and advanced-stage patients who received systemic therapy had 19.7 (95% CI = 12.7-27.4) and 22.0 (95% CI = 16.6-27.7) mean workdays lost, respectively. CONCLUSIONS: Productivity loss varies by stage and appears to be higher in early-stage patients who receive more intensive treatments in the first year following a new HCC diagnosis.


Sujet(s)
Carcinome hépatocellulaire , Bases de données factuelles , Rendement , Tumeurs du foie , Stadification tumorale , Humains , Carcinome hépatocellulaire/économie , Carcinome hépatocellulaire/diagnostic , Carcinome hépatocellulaire/épidémiologie , Carcinome hépatocellulaire/thérapie , Tumeurs du foie/économie , Tumeurs du foie/épidémiologie , Tumeurs du foie/thérapie , Mâle , Femelle , Études rétrospectives , Adulte d'âge moyen , Adulte , États-Unis , Absentéisme , Sujet âgé , Études de cohortes , Examen des demandes de remboursement d'assurance , Jeune adulte , Coûts indirects de la maladie
8.
Cancer Med ; 13(11): e7304, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38826094

RÉSUMÉ

BACKGROUND: The surge in omicron variants has caused nationwide breakthrough infections in mainland China since the December 2022. In this study, we report the neutralization profiles of serum samples from the patients with breast cancer and the patients with liver cancer who had contracted subvariant breakthrough infections. METHODS: In this real-world study, we enrolled 143 COVID-19-vaccinated (81 and 62 patients with breast and liver cancers) and 105 unvaccinated patients with cancer (58 and 47 patients with breast and liver cancers) after omicron infection. Anti-spike receptor binding domain (RBD) IgGs and 50% pseudovirus neutralization titer (pVNT50) for the preceding (wild type), circulating omicron (BA.4-BA.5, and BF.7), and new subvariants (XBB.1.5) were comprehensively analyzed. RESULTS: Patients with liver cancer receiving booster doses had higher levels of anti-spike RBD IgG against circulating omicron (BA.4-BA.5, and BF.7) and a novel subvariant (XBB.1.5) compared to patients with breast cancer after breakthrough infection. Additionally, all vaccinated patients produced higher neutralizing antibody titers against circulating omicron (BA.4-BA.5, and BF.7) compared to unvaccinated patients. However, the unvaccinated patients produced higher neutralizing antibody against XBB.1.5 than vaccinated patients after Omicron infection, with this trend being more pronounced in breast cancer than in liver cancer patients. Moreover, we found that there was no correlation between anti-spike RBD IgG against wildtype virus and the neutralizing antibody titer, but a positive correlation between anti-spike RBD IgG and the neutralizing antibody against XBB.1.5 was found in unvaccinated patients. CONCLUSION: Our study found that there may be differences in vaccine response and protective effect against COVID-19 infection in patients with liver and breast cancer. Therefore, we recommend that COVID-19 vaccine strategies should be optimized based on vaccine components and immunology profiles of different patients with cancer.


Sujet(s)
Anticorps neutralisants , Anticorps antiviraux , Tumeurs du sein , Vaccins contre la COVID-19 , COVID-19 , Tumeurs du foie , SARS-CoV-2 , Humains , Femelle , COVID-19/immunologie , COVID-19/épidémiologie , COVID-19/prévention et contrôle , COVID-19/virologie , Tumeurs du foie/virologie , Tumeurs du foie/immunologie , Tumeurs du foie/épidémiologie , Tumeurs du sein/immunologie , Tumeurs du sein/épidémiologie , Tumeurs du sein/virologie , SARS-CoV-2/immunologie , Anticorps neutralisants/sang , Anticorps neutralisants/immunologie , Adulte d'âge moyen , Anticorps antiviraux/sang , Anticorps antiviraux/immunologie , Chine/épidémiologie , Vaccins contre la COVID-19/immunologie , Adulte , Sujet âgé , Glycoprotéine de spicule des coronavirus/immunologie , Mâle , Épidémies de maladies , Immunoglobuline G/sang , Immunoglobuline G/immunologie
9.
J Prim Care Community Health ; 15: 21501319241259413, 2024.
Article de Anglais | MEDLINE | ID: mdl-38884145

RÉSUMÉ

INTRODUCTION/OBJECTIVES: Chronic hepatitis B virus infection (CHBVI) is a major public health problem affecting about 296 million people worldwide. HBV infects the liver, and when it becomes chronic, may cause cirrhosis and hepatocellular carcinoma (HCC). The aim of our study was to identify the risk factors and comorbid medical conditions that were associated with HCC in patients who had CHBVI. METHODS: We performed a retrospective electronic medical record review of adult patients diagnosed with CHBVI, who presented to our primary care office between October 1, 2017 and October 21, 2022. Selected variables in patients with CHBVI with HCC (HCC group) were compared to those without HCC (NoHCC group). RESULTS: Among 125 patients with CHBVI, 24% had HCC and 76% did not have HCC. There were higher frequencies of association of certain comorbidities in the HCC group compared to NoHCC group, such as anemia (63.3% vs 26.3%; P < .001), ascites (53.3% vs 1.1%; P < .001), portal hypertension (43.3% vs 0.0%; P < .001), chronic kidney disease (40.0% vs 13.7%; P = .002), and HCV coinfection (13.3% vs 7.4%; P < .001). The logistic regression model showed increased odds of HCC for each year of increase in age (OR = 1.06, 95% CI = 1.01-1.11; P = .014), and increased odds in men (OR = 5.96, 95% CI = 1.71-20.73; P = .005). Although Asians represented the racial majority in both the groups, there was no significant difference in the race distribution between the two groups. CONCLUSION: In patients with CHBVI, increasing age and male sex are factors associated with increased odds of having HCC. Patients with CHBVI and HCC have higher frequencies of association of tobacco use, recreational drug use, anemia, ascites, portal hypertension, chronic kidney disease, and co-infection with HCV.


Sujet(s)
Carcinome hépatocellulaire , Comorbidité , Hépatite B chronique , Tumeurs du foie , Humains , Mâle , Carcinome hépatocellulaire/épidémiologie , Femelle , Tumeurs du foie/épidémiologie , Adulte d'âge moyen , Études rétrospectives , Facteurs de risque , Hépatite B chronique/épidémiologie , Hépatite B chronique/complications , Adulte , Sujet âgé
10.
Int J Immunopathol Pharmacol ; 38: 3946320241265263, 2024.
Article de Anglais | MEDLINE | ID: mdl-38898405

RÉSUMÉ

Background: Hepatocellular carcinoma (HCC) is the most common and fatal primary liver cancer. Genetic variants of DNA repair systems can reduce DNA repair capability and increase HCC risk. Objectives: This study aimed to examine, in Egyptian hepatitis C virus (HCV) patients, the relationship between the X-ray repair cross-complementing group 1 (XRCC1) rs1799782 single nucleotide polymorphism (SNP) and HCC susceptibility. Methods: We included 100 adult HCV-positive patients with HCC and 100 adult HCV-positive patients with liver cirrhosis as pathological controls. XRCC1 rs1799782 SNP genotyping was done in both groups using quantitative real-time PCR (qPCR). The distribution of genotypes in patients and controls was compared using several inheritance models. Results: We found that the CT genotype, when analyzed under both the co-dominant (OR (95 % CI): 2.147 (1.184-3.893), p = .012) and the over-dominant (OR (95 % CI): 2.055 (1.153-3.660), p = .015) models, as well as the combined CT and TT genotypes under the dominant model (OR (95 % CI) of 1.991 (1.133-3.497), p = .017), were associated with increased susceptibility to HCC. The frequency of the T allele was higher among HCC participants (32%) compared to those with cirrhosis (23.5%) and carrying the T allele increased the risk of HCC by 1.532 times, however, these associations did not reach statistical significance (p-values >0.05). Moreover, the variant T allele was associated with worse clinical manifestations and laboratory results among the HCC group, but AFP levels were not affected significantly. Conclusions: Egyptians with XRCC1 rs1799782 SNP may have a higher risk of HCV-related HCC. More extensive multi-center prospective investigations must confirm this association.


Sujet(s)
Carcinome hépatocellulaire , Prédisposition génétique à une maladie , Tumeurs du foie , Polymorphisme de nucléotide simple , Protéine-1 de complémentation croisée de la réparation des lésions induites par les rayons X , Humains , Carcinome hépatocellulaire/génétique , Carcinome hépatocellulaire/virologie , Carcinome hépatocellulaire/épidémiologie , Protéine-1 de complémentation croisée de la réparation des lésions induites par les rayons X/génétique , Tumeurs du foie/génétique , Tumeurs du foie/virologie , Tumeurs du foie/épidémiologie , Mâle , Études cas-témoins , Égypte , Femelle , Adulte d'âge moyen , Projets pilotes , Adulte , Hépatite C/complications , Hépatite C/génétique , Facteurs de risque , Génotype
11.
Sci Rep ; 14(1): 13232, 2024 06 09.
Article de Anglais | MEDLINE | ID: mdl-38853169

RÉSUMÉ

Hepatocellular carcinoma (HCC) is a common malignancy with poor survival and requires long-term follow-up. Hence, we collected information on patients with Primary Hepatocellular Carcinoma in the United States from the Surveillance, Epidemiology, and EndResults (SEER) database. We used this information to establish a deep learning with a multilayer neural network (the NMTLR model) for predicting the survival rate of patients with Primary Hepatocellular Carcinoma. HCC patients pathologically diagnosed between January 2011 and December 2015 in the SEER (Surveillance, Epidemiology, and End Results) database of the National Cancer Institute of the United States were selected as study subjects. We utilized two deep learning-based algorithms (DeepSurv and Neural Multi-Task Logistic Regression [NMTLR]) and a machine learning-based algorithm (Random Survival Forest [RSF]) for model training. A multivariable Cox Proportional Hazards (CoxPH) model was also constructed for comparison. The dataset was randomly divided into a training set and a test set in a 7:3 ratio. The training dataset underwent hyperparameter tuning through 1000 iterations of random search and fivefold cross-validation. Model performance was assessed using the concordance index (C-index), Brier score, and Integrated Brier Score (IBS). The accuracy of predicting 1-year, 3-year, and 5-year survival rates was evaluated using Receiver Operating Characteristic (ROC) curves, calibration plots, and Area Under the Curve (AUC). The primary outcomes were the 1-year, 3-year, and 5-year overall survival rates. Models were developed using DeepSurv, NMTLR, RSF, and Cox Proportional Hazards regression. Model differentiation was evaluated using the C-index, calibration with concordance plots, and risk stratification capability with the log-rank test. The study included 2197 HCC patients, randomly divided into a training cohort (70%, n = 1537) and a testing cohort (30%, n = 660). Clinical characteristics between the two cohorts showed no significant statistical difference (p > 0.05). The deep learning models outperformed both RSF and CoxPH models, with C-indices of 0.735 (NMTLR) and 0.731 (DeepSurv) in the test dataset. The NMTLR model demonstrated enhanced accuracy and well-calibrated survival estimates, achieving an Area Under the Curve (AUC) of 0.824 for 1-year survival predictions, 0.813 for 3-year, and 0.803 for 5-year survival rates. This model's superior calibration and discriminative ability enhance its utility for clinical prognostication in Primary Hepatocellular Carcinoma. We deployed the NMTLR model as a web application for clinical practice. The NMTLR model have potential advantages over traditional linear models in prognostic assessment and treatment recommendations. This novel analytical approach may provide reliable information on individual survival and treatment recommendations for patients with primary liver cancer.


Sujet(s)
Carcinome hépatocellulaire , Apprentissage profond , Tumeurs du foie , Programme SEER , Humains , Carcinome hépatocellulaire/mortalité , Carcinome hépatocellulaire/anatomopathologie , Tumeurs du foie/mortalité , Tumeurs du foie/anatomopathologie , Tumeurs du foie/épidémiologie , Femelle , Mâle , Adulte d'âge moyen , Sujet âgé , Pronostic , Modèles des risques proportionnels , États-Unis/épidémiologie , Bases de données factuelles , Taux de survie ,
12.
Front Endocrinol (Lausanne) ; 15: 1400573, 2024.
Article de Anglais | MEDLINE | ID: mdl-38841303

RÉSUMÉ

Background and aims: Liver hepatocellular carcinoma (LIHC) exhibits a multifactorial etiology, insidious onset, and a significantly low 5-year survival rate. We aimed to evaluate the causal impact of exposure factors (Alzheimer's disease, platelet count, ambidextrousness, cigarettes smoked per day, alcohol consumption, and endocarditis) on the risk of LIHC using a two-sample Mendelian randomization (MR) study. Methods: Independent single nucleotide polymorphisms (SNPs) strongly associated with Alzheimer's disease, platelet count, ambidextrousness, daily cigarette consumption, alcohol intake, and endocarditis were selected as instrumental variables (IVs) from the corresponding genome-wide association studies (GWAS). Genetic summary statistics for LIHC came from a GWAS that included 168 cases and 372,016 controls of European individuals. Multivariable MR analyses were performed to find the causal association between 6 exposure factors and LIHC risk. The inverse-variance weighted (IVW)-MR was employed as the primary analysis, and the MR-Egger regression, LASSO regression, and weighted Median approaches were performed as complementary analyses. Results: Multivariable MR analysis showed causal association between Alzheimer's disease [Odds ratio (OR) = 0.9999, 95% confidence intervals (CI) = 0.9998-0.9999, p = 0.0010], platelet count (OR = 0.9997, 95% CI = 0.9995-0.9999, p = 0.0066), alcohol consumption (OR = 0.9994, 95% CI = 0.9990-0.9999, p = 0.0098) and the LIHC outcome. After IVW-MR, MR-Egger and LASSO tests, the results are still significant. Next, we used different MR Methods to analyze platelet count, alcohol consumption, and Alzheimer's disease separately. Moreover, both funnel plots and MR-Egger intercepts provided compelling evidence to refute the presence of directional pleiotropy in the association between platelet count, alcohol consumption, Alzheimer's disease and the risk of LIHC. The IVW-MR analysis revealed a significant causal association between an elevated platelet count and a reduced risk of LIHC (OR = 0.9996, 95% CI= 0.9995-0.9998, p = 0.0005). Similarly, the analysis of weighted median revealed a negative correlation between platelet count and the risk of LIHC (OR = 0.9995, 95% CI = 0.9993-0.9999; p = 0.0160). Conversely, we observed a positive causal effect of alcohol consumption on the incidence of LIHC (OR = 1.0004, 95% CI = 0.9999-1.0009). However, no significant causal relationship was found between alcohol assumption, Alzheimer's disease, and LIHC susceptibility. Conclusions: A significant causal relationship exists between platelet count, alcohol consumption, Alzheimer's disease, and an increased risk of LIHC. The study presents compelling evidence for a genetically predicted decreased susceptibility to LIHC based on platelet count. The research implies that elevated platelet count may serve as a protective mechanism against LIHC. These findings may inform clinical strategies for LIHC prevention.


Sujet(s)
Consommation d'alcool , Carcinome hépatocellulaire , Étude d'association pangénomique , Tumeurs du foie , Analyse de randomisation mendélienne , Polymorphisme de nucléotide simple , Humains , Tumeurs du foie/génétique , Tumeurs du foie/épidémiologie , Tumeurs du foie/sang , Tumeurs du foie/étiologie , Carcinome hépatocellulaire/sang , Carcinome hépatocellulaire/génétique , Carcinome hépatocellulaire/épidémiologie , Carcinome hépatocellulaire/étiologie , Consommation d'alcool/effets indésirables , Numération des plaquettes , Facteurs de risque
13.
Zhonghua Liu Xing Bing Xue Za Zhi ; 45(6): 865-869, 2024 Jun 10.
Article de Chinois | MEDLINE | ID: mdl-38889988

RÉSUMÉ

Liver cancer is a significant contributor to the world's cancer burden. In order to comprehend the variations in its regional, age, gender, and histological subtype distributions as well as its temporal trend, this paper analyzes the worldwide statistical data of liver cancer, including the incidence, mortality, and survival. The findings indicated that the stages of liver cancer control and prevention are heterogeneous among countries and regions. The successful experience of liver cancer control and prevention in some countries should be promoted and disseminated. According to the various national conditions, comprehensive intervention measures, including reducing aflatoxin exposure, promoting vaccination, improving the treatment of chronic hepatitis infection, and implementing early diagnosis and treatment of liver cancer, should be developed.


Sujet(s)
Tumeurs du foie , Humains , Tumeurs du foie/épidémiologie , Incidence , Santé mondiale , Femelle , Mâle
14.
Math Biosci Eng ; 21(4): 5207-5226, 2024 Mar 06.
Article de Anglais | MEDLINE | ID: mdl-38872533

RÉSUMÉ

Hepatitis B is one of the global health issues caused by the hepatitis B virus (HBV), producing 1.1 million deaths yearly. The acute and chronic phases of HBV are significant because worldwide, approximately 250 million people are infected by chronic hepatitis B. The chronic stage is a long-term, persistent infection that can cause liver damage and increase the risk of liver cancer. In the case of multiple phases of infection, a generalized saturated incidence rate model is more reasonable than a simply saturated incidence because it captures the complex dynamics of the different infection phases. In contrast, a simple saturated incidence rate model assumes a fixed shape for the incidence rate curve, which may not accurately reflect the dynamics of multiple infection phases. Considering HBV and its various phases, we constructed a model to present the dynamics and control strategies using the generalized saturated incidence. First, we proved that the model is well-posed. We then found the reproduction quantity and model equilibria to discuss the time dynamics of the model and investigate the conditions for stabilities. We also examined a control mechanism by introducing various controls to the model with the aim to increase the population of those recovered and minimize the infected people. We performed numerical experiments to check the biological significance and control implementation.


Sujet(s)
Simulation numérique , Virus de l'hépatite B , Hépatite B , Humains , Incidence , Hépatite B/épidémiologie , Hépatite B chronique/épidémiologie , Taux de reproduction de base/statistiques et données numériques , Tumeurs du foie/épidémiologie , Modèles biologiques , Algorithmes
16.
Aliment Pharmacol Ther ; 60(2): 212-223, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38693757

RÉSUMÉ

BACKGROUND: Adverse outcomes of cirrhosis remain a top priority. AIMS: We examined the distribution of cirrhosis causes, HCC incidence and mortality and related changes over time in a nationwide U.S. METHODS: A retrospective study of a national sample of commercially insured patients with cirrhosis from Optum's de-identified Clinformatics® Data Mart Database (CDM). RESULTS: A total of 628,743 cirrhosis cases were identified with 45% having NAFLD, 19.5% HCV, and 16.3% ALD. African Americans had the highest rate of decompensation (60.6%), while Asians had the highest rate of HCC (2.4%), both p < 0.001. African Americans more frequently had HCV (28.4%) while Hispanic/Latinos more frequently had NAFLD (49.2%, p < 0.001). Patients in the 2014-2021 cohort were significantly older (63.0 ± 12.8 vs. 57.0 ± 14.3), less frequently decompensated (54.5% vs. 58.3%) but more frequently had HCC (1.7% vs. 0.6%) and NAFLD (46.5% vs. 44.2%), all p < 0.001. The overall annual incidence of HCC was 0.76% (95% CI: 0.75-0.77) with a 5-year cumulative incidence of 4.03% (95% CI: 3.98-4.09), with significant variation by sex, race/ethnicity, and cirrhosis aetiology. The overall median years of survival were 11.4 (95% CI: 11.3-11.5) with a 5-year cumulative survival of 73.4% (95% CI: 73.3%-73.6%), also with significant disparities in similar subgroups (lowest in cryptogenic cirrhosis and worse in 2014-2021 vs. 2003-2013). The 2014-2021 period was independently associated with worse survival (aHR: 1.14, 95% CI: 1.08-1.20). CONCLUSIONS: HCC incidence and survival vary by aetiology among patients with cirrhosis, with cryptogenic cirrhosis having the lowest survival and lower survival in the more recent time period.


Sujet(s)
Carcinome hépatocellulaire , Cirrhose du foie , Tumeurs du foie , Humains , Mâle , Femelle , Cirrhose du foie/mortalité , Cirrhose du foie/épidémiologie , Cirrhose du foie/complications , Adulte d'âge moyen , Études rétrospectives , États-Unis/épidémiologie , Sujet âgé , Tumeurs du foie/mortalité , Tumeurs du foie/épidémiologie , Incidence , Carcinome hépatocellulaire/mortalité , Carcinome hépatocellulaire/épidémiologie , Taux de survie , Stéatose hépatique non alcoolique/mortalité , Stéatose hépatique non alcoolique/épidémiologie , Stéatose hépatique non alcoolique/complications , Adulte
17.
PLoS One ; 19(5): e0295648, 2024.
Article de Anglais | MEDLINE | ID: mdl-38820519

RÉSUMÉ

BACKGROUND: Gender disparity is pervasive in academic medicine. This study aimed to assess the disparity between men and women with regard to first and senior author positions in primary studies on liver cancer over the last two decades. METHODS: We conducted a review of articles published in high-impact factor journals of the field of Gastroenterology and Hepatology in 2005, 2010, 2015 and 2020. First and senior authors of all ages were considered as the study population. The authors' genders were determined using the online artificial intelligence tool genderize.io (https://genderize.io/). The disparity between men and women authors was assessed using the linear-by-linear association test. RESULTS: 665 original articles from 10 journals were reviewed. The point prevalence of first women authors was 25.0% compared with 75.0% for men. The point prevalence of senior women authors was 16.3% compared with 83.7% for men. From 2000 to 2020, the proportion of first women authors increased 14.4% to 26.8% compared with 85.6%-73.2% for men (P = 0.009), and the proportion of senior women authors increased from 7.4% to 19.5%, compared with 92.6%-80.5% for men (P = 0.035). The factor independently associated with a reduced representation of women among first authors was the region of author. The factor independently associated with a reduced representation of women among senior authors was the impact factor of journals. CONCLUSION: The findings indicated a remarkable increase in the proportion of women, both first and senior authors, over the past two decades in the field of liver cancers. However, the representation of women authors in this area is far less than that of men.


Sujet(s)
Gastroentérologie , Tumeurs du foie , Humains , Femelle , Mâle , Tumeurs du foie/épidémiologie , Gastroentérologie/statistiques et données numériques , Auteur , Périodiques comme sujet/statistiques et données numériques , Facteur d'impact , Facteurs sexuels , Sexisme/statistiques et données numériques , Recherche biomédicale
18.
J Nutr Health Aging ; 28(6): 100261, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38810511

RÉSUMÉ

OBJECTIVE: Liver cancer is the world's sixth most prevalent cancer and the third most frequent cause of cancer-related mortality. Glucose metabolic disorders, indicated by a high fasting plasma glucose (HFPG) concentration, is a contributor to the etiology of liver cancer. With the rising prevalence of glucose metabolic disorders, an assessment of the global burden of liver cancer attributable to HFPG is warranted to inform global liver cancer prevention and control strategies. METHODS AND ANALYSIS: We evaluated the global death and disability-adjusted life years (DALYs) of liver cancer and its subtypes attributable to HFPG at global, regional, and country level. The temporal trend and disparity across geographic regions, social development level, age groups and sex were assessed. RESULTS: In 2019, HFPG-attributable liver cancer was estimated to have caused 4,729.49 deaths and to be responsible for 99,302.25 DALYs. The age-standardized mortality and DALY rate were 0.06 and 1.20 per 100,000 population, and displayed a significantly increasing temporal trend from 1990 to 2019. The age-standardized mortality rate of patients with liver cancer that was attributable to HFPG was higher in men than women. Sex-based disparity narrowed after the women reached menopause, but increased between 1990 and 2019. CONCLUSION: The burden of liver cancer that are attributable to HFPG has been influenced by longitudinal changes in lifestyle, the etiology of liver disease, age demographics, and hormonal status in women. These findings suggest that comprehensive strategies could be implemented, especially for patients with NASH and hyperglycemia, to prevent liver cancer.


Sujet(s)
Glycémie , Jeûne , Charge mondiale de morbidité , Tumeurs du foie , Humains , Tumeurs du foie/épidémiologie , Tumeurs du foie/sang , Tumeurs du foie/étiologie , Mâle , Femelle , Glycémie/analyse , Glycémie/métabolisme , Adulte d'âge moyen , Sujet âgé , Jeûne/sang , Santé mondiale/statistiques et données numériques , Espérance de vie corrigée de l'incapacité , Adulte , Sujet âgé de 80 ans ou plus , Prévalence
19.
J Epidemiol Glob Health ; 14(2): 398-410, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38713342

RÉSUMÉ

BACKGROUND: Type 2 diabetes mellitus (T2DM) increases the risk of liver cancer among people living with hepatitis B virus (HBV). Our study aimed to estimate the global burden and trends of liver cancer attributable to comorbid T2DM among people living with HBV from 1990 to 2019. METHODS: We calculated the population attributable fractions (PAFs) of liver cancer attributable to comorbid T2DM among the burden of HBV-related liver cancer. We applied the PAFs to the burden of HBV-related liver cancer derived from the Global Burden of Disease (GBD) 2019 database to obtain the burden of liver cancer attributable to HBV-T2DM comorbidity. The prevalence, disability-adjusted life year (DALY), and deaths of liver cancer attributable to the comorbidity were assessed at the global, regional, and country levels and then stratified by the sociodemographic index (SDI), sex, and age group. Estimated annual percentage changes (EAPCs) were calculated to quantify the temporal trends. RESULTS: In 2019, the global age-standardized prevalence and DALY rates of liver cancer attributable to HBV-T2DM comorbidity were 9.9 (8.4-11.5) and 182.4 (154.9-212.7) per 10,000,000 individuals, respectively. High-income Asia Pacific and East Asia had the highest age-standardized prevalence and DALY rates of liver cancer attributable to HBV-T2DM comorbidity, respectively. From 1990 to 2019, age-standardized prevalence and DALY rates increased in 16 out of 21 GBD regions. High-income North America had the largest annual increases in both age-standardized prevalence rates (EAPC = 6.07; 95% UI, 5.59 to 6.56) and DALY rates (EAPC = 4.77; 95% UI, 4.35 to 5.20), followed by Australasia and Central Asia. Across all SDI regions, the high SDI region exhibited the most rapid increase in age-standardized prevalence and DALY rates from 1990 to 2019. Additionally, men had consistently higher disease burdens than women across all age groups. The patterns of mortality burden and trends are similar to those of DALYs. CONCLUSIONS: The burden of liver cancer attributable to comorbid T2DM among people living with HBV has exhibited an increasing trend across most regions over the last three decades. Tailored prevention strategies targeting T2DM should be implemented among individuals living with HBV.


Sujet(s)
Comorbidité , Diabète de type 2 , Charge mondiale de morbidité , Tumeurs du foie , Humains , Diabète de type 2/épidémiologie , Tumeurs du foie/épidémiologie , Mâle , Femelle , Charge mondiale de morbidité/tendances , Adulte d'âge moyen , Prévalence , Adulte , Sujet âgé , Santé mondiale/statistiques et données numériques , Hépatite B/épidémiologie , Espérance de vie corrigée de l'incapacité/tendances
20.
Chin Med J (Engl) ; 137(12): 1414-1420, 2024 Jun 20.
Article de Anglais | MEDLINE | ID: mdl-38766992

RÉSUMÉ

BACKGROUND: Hepatitis B virus (HBV) infection is the primary cause of hepatocellular carcinoma (HCC) in China. The target population for HCC screening comprises individuals who test positive for hepatitis B surface antigen (HBsAg). However, current data on the prevalence of HBV infection among individuals who are eligible for HCC screening in China are lacking. We aimed to assess the seroepidemiology of HBV infection among Chinese individuals eligible for HCC screening to provide the latest evidence for appropriate HCC screening strategies in China. METHODS: Questionnaires including information of sex, age, ethnicity, marital status, educational level, source of drinking water, as well as smoking and alcohol consumption history and serum samples were collected from females aged 45-64 years and males aged 35-64 years in 21 counties from 4 provinces in eastern and central China between 2015 and 2023. Enzyme-linked immunosorbent assay methods were used to detect the serum HBV marker HBsAg. RESULTS: A total of 603,082 individuals were enrolled, and serum samples were collected for analysis from January 1, 2015 to December 31, 2023. The prevalence of HBsAg positive in the study population was 5.23% (31,528/603,082). The prevalence of HBsAg positive was greater in males than in females (5.60% [17,660/315,183] vs . 4.82% [13,868/287,899], χ 2  = 187.52, P  <0.0001). The elderly participants exhibited a greater prevalence of HBV infection than younger participants (χ 2  = 41.73, P  <0.0001). Birth cohort analysis revealed an overall downward trend in HBV prevalence for both males and females. Individuals born in more recent cohorts exhibited a lower prevalence of HBV infection as compared to those born earlier. CONCLUSIONS: The current prevalence of HBV infection remains above 5% in populations eligible for HCC screening in China. Further efforts should be made to increase the accessibility of HCC screening among individuals with HBV infection.


Sujet(s)
Antigènes de surface du virus de l'hépatite B , Hépatite B , Tumeurs du foie , Humains , Mâle , Femelle , Adulte d'âge moyen , Chine/épidémiologie , Tumeurs du foie/épidémiologie , Tumeurs du foie/virologie , Tumeurs du foie/sang , Hépatite B/épidémiologie , Études transversales , Adulte , Antigènes de surface du virus de l'hépatite B/sang , Virus de l'hépatite B , Prévalence , Carcinome hépatocellulaire/épidémiologie , Carcinome hépatocellulaire/virologie , Dépistage précoce du cancer/méthodes , Enquêtes et questionnaires , Études séroépidémiologiques
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...